Indicators
Indicators
Value
Direction
MACD(12,26,9)
-6.202
Sell
RSI(14)
36.888
Neutral
STOCH(KDJ)(9,3,3)
25.945
Neutral
ATR(14)
8.571
High Vlolatility
CCI(14)
-90.671
Neutral
Williams %R
63.250
Sell
TRIX(12,20)
-0.902
Sell
StochRSI(14)
75.494
Buy
Search
Insmed Inc
INSMAdd to Watchlist
116.710USD
+0.710+0.61%
Market hours （ET）Quotes delayed by 15 min
25.27BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Insmed Inc
Currency: USD Updated: 2026-05-12Key Insights
Insmed Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 22 out of 383 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 205.83.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Insmed Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Insmed Inc Highlights
StrengthsRisks
Insmed Incorporated is a global biopharmaceutical company. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company’s pre-clinical research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 as well as pre-clinical research programs.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 98.69% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 606.42M.
Undervalued
The company’s latest PE is -20.15, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 226.45M shares, decreasing 3.77% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 1.17K shares of this stock.
Analyst Rating
Based on
22
analysts
Buy
Current Rating
205.830
Target Price
+103.09%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-12The current financial score of Insmed Inc is 7.31, ranking 99 out of 383 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 305.96M, representing a year-over-year increase of 229.62%, while its net profit experienced a year-over-year increase of 36.25%.
Score
Financials
5.80
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.82
Operational Efficiency
5.60
Growth Potential
9.84
Shareholder Returns
7.48
Insmed Inc's Company Valuation
Currency: USD Updated: 2026-05-12The current valuation score of Insmed Inc is 7.14, ranking 154 out of 383 in the Biotechnology & Medical Research industry. Its current P/E ratio is -20.15, which is -81.31% below the recent high of -3.77 and -69.83% above the recent low of -34.23.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 22/383
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-12The current earnings forecast score of Insmed Inc is 8.64, ranking 90 out of 383 in the Biotechnology & Medical Research industry. The average price target is 216.50, with a high of 256.00 and a low of 144.21.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
22
analysts
Buy
Current Rating
205.830
Target Price
+103.09%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Insmed Inc
INSM
22
CRISPR Therapeutics AG
CRSP
29
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-12The current price momentum score of Insmed Inc is 7.29, ranking 105 out of 383 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 147.42 and the support level at 91.74, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
112.666
Buy
MA10
124.740
Sell
MA20
132.981
Sell
MA50
142.625
Sell
MA100
152.433
Sell
MA200
155.898
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-12The current institutional shareholding score of Insmed Inc is 10.00, ranking 1 out of 383 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 104.47%, representing a quarter-over-quarter increase of 0.02%. The largest institutional shareholder is PRFDX, holding a total of 3.85M shares, representing 1.78% of shares outstanding, with 74.66% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-12The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Insmed Inc is 5.93, ranking 32 out of 383 in the Biotechnology & Medical Research industry. The company's beta value is 0.84. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.84
VaR
+4.40%
240-Day Maximum Drawdown
+52.06%
240-Day Volatility
+54.82%
Return
Best Daily Return
60 days
+11.66%
120 days
+11.66%
5 years
+118.45%
Worst Daily Return
60 days
-23.41%
120 days
-23.41%
5 years
-23.41%
Sharpe Ratio
60 days
-0.97
120 days
-1.46
5 years
+0.73
Risk Assessment
Maximum Drawdown
240 days
+52.06%
3 years
+52.06%
5 years
+52.06%
Return-to-Drawdown Ratio
240 days
+1.44
3 years
+3.05
5 years
+1.43
Skewness
240 days
+0.94
3 years
+15.20
5 years
+13.90
Volatility
Realised Volatility
240 days
+54.82%
5 years
+62.75%
Standardised True Range
240 days
+4.87%
5 years
+2.06%
Downside Risk-Adjusted Return
120 days
-157.28%
240 days
-157.28%
Maximum Daily Upside Volatility
60 days
+48.34%
Maximum Daily Downside Volatility
60 days
+57.20%
Liquidity
Average Turnover Rate
60 days
+1.25%
120 days
+1.35%
5 years
--
Turnover Deviation
20 days
+5.19%
60 days
-4.87%
120 days
+2.87%
Peer Comparison
Biotechnology & Medical Research
Insmed Inc
INSM
7.68 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.75 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.54 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
